Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity (Q38619054)

4 September 2017

Bupropion-SR plus naltrexone-SR for the treatment of mild-to-moderate obesity (English)

1 reference

4 September 2017

0 references

0 references

Khawla F Ali

1

1 reference

4 September 2017

Alpana P Shukla

series ordinal

2

1 reference

4 September 2017

Louis J Aronne

series ordinal

3

1 reference

4 September 2017

language of work or name

English

0 references

publication date

29 October 2015

1 reference

Expert Review of Clinical Pharmacology

4 September 2017

1 reference

4 September 2017

9

1 reference

4 September 2017

27-34

1 reference

4 September 2017

1

1 reference

Annual medical spending attributable to obesity: payer-and service-specific estimates

4 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Hypothalamic opioid-melanocortin appetitive balance and addictive craving

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Rational design of a combination medication for the treatment of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Differential expression and sensitivity of presynaptic and postsynaptic opioid receptors regulating hypothalamic proopiomelanocortin neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

The central melanocortin system and the integration of short- and long-term regulators of energy homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Targeted disruption of the melanocortin-4 receptor results in obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Anti-obesity drugs: past, present and future

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

New medications for treatment of obesity: metabolic and cardiovascular effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Reduced dopaminergic tone in hypothalamic neural circuits: expression of a "thrifty" genotype underlying the metabolic syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Bilateral hypothalamic dopamine infusion in male Zucker rat suppresses feeding due to reduced meal size.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Modulation of eating by central catecholamine systems

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Safety profile of sustained-release bupropion in depression: results of three clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Efficacy of maintenance treatment with naltrexone for opioid dependence: a meta-analytical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Naltrexone for the management of alcohol dependence

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Reward systems and food intake: role of opioids

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Long-term feed intake regulation in sheep is mediated by opioid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Suppression of deprivation-induced food and water intake in rats and mice by naloxone

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effects of naltrexone on food intake and body weight gain in olanzapine-treated rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effect of naltrexone on food intake, hunger, and satiety in obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effects of long-term therapy with naltrexone on body weight in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Naltrexone and human eating behavior: a dose-ranging inpatient trial in moderately obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Bariatric surgery and long-term cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

Metabolic effects of bariatric surgery in patients with moderate obesity and type 2 diabetes: analysis of a randomized control trial comparing surgery with intensive medical treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F17512433.2016.1100072

10.1586/17512433.2016.1100072

21 January 2018

Identifiers

DOI

1 reference

release_al4aor6vljazhgzdjlheuirdee

4 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/al4aor6vljazhgzdjlheuirdee

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference